Scientist · Seattle, WA

Gabriela Henriquez

Biopharmaceutical scientist focused on process development, gene therapy, and translational research.

Currently exploring opportunities in biopharmaceutical process development.

Early-career scientist with hands-on expertise in mammalian cell culture, flow cytometry, in vivo models, and molecular biology — applied across academic and GLP/GMP industry settings, including AAV process development.

Portrait of Gabriela Henriquez

About

Bio

Gabriela Henriquez is an early-career scientist based in Seattle, Washington, focused on biopharmaceutical process development, gene therapy, and translational research. Her hands-on experience spans mammalian cell culture, flow cytometry, in vivo models, and molecular biology — applied across both academic and regulated GLP/GMP industry settings.

She most recently supported AAV workflow optimization as a Gene Delivery & Editing Process Development intern at Bristol Myers Squibb. Previously, she served as a Quality Assurance Specialist II at Seattle Children's Research Institute, and earned her Ph.D. in Environmental Science & Engineering at The University of Texas at El Paso, where her dissertation explored the molecular mechanisms of neuronal toxicity and neurodegeneration.

Gabriela's published work — appearing in ACS Chemical Neuroscience, ACS Omega, Biomaterials Advances, and Molecules — investigates neuroprotective compounds, amyloid pathology, and nanomaterial-based delivery systems. A selection is listed below, with the full record available on Google Scholar.

Recent updates

  1. Aug 2025 Completed Gene Delivery & Editing Process Development internship at Bristol Myers Squibb, supporting AAV workflow optimization through high-throughput screening.
  2. Jun 2025 Joined Bristol Myers Squibb (Seattle) as a Gene Delivery & Editing Process Development intern.
  3. Mar 2024 Concluded role as Quality Assurance Specialist II at Seattle Children's Research Institute after improving documentation systems and increasing compliance rate by 75%.
  4. 2023 Published a review on α-synuclein immunotherapy as a therapeutic approach for Parkinson's disease in Exploration of Neuroprotective Therapy.
  5. 2022 Two first-author papers published in ACS Chemical Neuroscience on carbon quantum dots and amyloid cross-toxicity, plus a co-authored study in Biomaterials Advances.
  6. May 2022 Joined Seattle Children's Research Institute as Quality Assurance Specialist II.
  7. Dec 2021 Completed Ph.D. in Environmental Science & Engineering at The University of Texas at El Paso. Dissertation: The Role of Xenobiotics in Neurodegenerative Diseases.
  • 9+ Peer-reviewed publications
  • 550+ Citations on Google Scholar
  • 5+ Years research experience
  • 2+ Years GLP/GMP industry

Experience

Where I've worked

  1. Jun 2025 – Aug 2025

    Seattle, WA

    Bristol Myers Squibb

    Gene Delivery & Editing Process Development, Intern

    Bristol Myers Squibb

    • Supported Adeno-Associated Virus (AAV) workflow optimization, contributing to improved viral yield and purity using high-throughput screening.
    • Applied statistical tools (JMP) to analyze experimental results and summarize findings.
    • Documented research in electronic lab notebooks (ELN) and communicated data insights to the team.
    • Presented experimental progress in weekly team meetings and incorporated feedback into project direction.
  2. May 2022 – Mar 2024

    Seattle, WA

    Seattle Children's

    Quality Assurance Specialist II

    Seattle Children's Research Institute

    • Maintained and updated standard operating procedures (SOPs) and quality records, ensuring regulatory compliance.
    • Improved documentation and reporting systems, achieving a 75% increase in compliance rate.
    • Collaborated with cross-functional teams to support process development and regulatory adherence.
  3. Jul 2016 – Dec 2021

    El Paso, TX

    Graduate Research & Teaching Assistant

    The University of Texas at El Paso (UTEP)

    • Conducted translational neuroscience research using in vitro and in vivo models to study neurodegeneration, synaptic dysfunction, and behavioral outcomes.
    • Developed and optimized behavioral and molecular assays to evaluate neuroprotective compounds, leading to peer-reviewed publications.
    • Performed rodent handling, small-animal surgery, and behavioral assays under IACUC-approved protocols; tissue collection and processing for downstream analyses.
    • Maintained C. elegans strains to study gene function in disease models; used fluorescence microscopy to analyze protein expression in transgenic worms.
    • Oversaw lab operations, inventory, and training; taught chemistry laboratory sections of 20+ students.

Education

Academic background

Ph.D., Environmental Science & Engineering

The University of Texas at El Paso (UTEP)

El Paso, Texas

Dissertation: The Role of Xenobiotics in Neurodegenerative Diseases.
Focus: molecular mechanisms of neuronal toxicity and neurodegeneration.

B.S., Pharmaceutical Biochemistry

Universidad Tecnológica de Santiago (UTESA)

Santiago, Dominican Republic

Certificates in Biotechnology & Biomanufacturing

Shoreline Community College

Shoreline, Washington

  • Biotechnology Laboratory Specialist Certificate
  • Essentials of Biomanufacturing Certificate

Skills

Technical expertise

Cell & Molecular Biology

  • Mammalian cell culture
  • Media preparation
  • DNA / RNA isolation
  • PCR & qPCR
  • Gel electrophoresis
  • Western blot
  • Transfection & transformation
  • Molecular cloning
  • Protein purification
  • ELISA
  • Immunofluorescence
  • Cytotoxicity assays
  • Aseptic technique

Equipment & Lab Operations

  • Flow cytometry
  • Fluorescence microscopy
  • Staining & imaging
  • High-throughput automation
  • Spectrophotometer
  • Live-cell imaging & analysis
  • Plate-based assays
  • ÄKTA chromatography
  • Bioreactor exposure
  • Supply inventory & ordering

Data, Software & Compliance

  • Experimental design (DOE)
  • Statistical analysis
  • Prism
  • R
  • JMP
  • BLAST
  • ImageJ
  • FlowJo
  • Electronic lab notebooks
  • GLP / GMP
  • SOP development & review
  • Good documentation practices

Publications

Selected peer-reviewed work

A selection of publications. For the complete and up-to-date list, visit my Google Scholar profile.

  1. Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson's disease

    G. Henriquez, M. Narayan. Exploration of Neuroprotective Therapy, 3(4), 207–234, 2023. Cited 24+

  2. Citric Acid–Derived Carbon Quantum Dots Attenuate Paraquat-Induced Neuronal Compromise In Vitro and In Vivo

    G. Henriquez, J. Ahlawat, R. Fairman, M. Narayan. ACS Chemical Neuroscience, 13(16), 2399–2409, 2022. Cited 41+

  3. Preclinical Model to Evaluate Outcomes of Amyloid Cross-Toxicity in the Rodent Brain

    G. Henríquez, L. Méndez, E. Castañeda, A. Wagler, S. Jeon, M. Narayan. ACS Chemical Neuroscience, 13(20), 2962–2973, 2022.

  4. Gelatin-derived carbon quantum dots mitigate herbicide-induced neurotoxic effects in vitro and in vivo

    J. Ahlawat, G. Henriquez, A. Varela-Ramirez, R. Fairman, M. Narayan. Biomaterials Advances, 137, 212837, 2022. Cited 24+

  5. Potential role of natural polyphenols against protein aggregation toxicity: in vitro, in vivo, and clinical studies

    G. Henríquez, A. Gomez, E. Guerrero, M. Narayan. ACS Chemical Neuroscience, 11(19), 2915–2934, 2020. Cited 81+

  6. Neuroprotective effect of brazilin on amyloid β (25–35)-induced pathology in a human neuroblastoma model

    G. Henríquez, L. Mendez, A. Varela-Ramirez, E. Guerrero, M. Narayan. ACS Omega, 5(23), 13785–13792, 2020. Cited 31+

  7. Testing amyloid cross-toxicity in the vertebrate brain

    G. Henriquez, L. Mendez, A. N. Schmid, E. D. Guerrero, S. A. Collins, et al. ACS Omega, 5(25), 15586–15591, 2020.

  8. Enhancing the delivery of chemotherapeutics: role of biodegradable polymeric nanoparticles

    J. Ahlawat, G. Henriquez, M. Narayan. Molecules, 23(9), 2157, 2018. Cited 163+

  9. Looking back, looking forward at halogen bonding in drug discovery

    L. Mendez, G. Henriquez, S. Sirimulla, M. Narayan. Molecules, 22(9), 1397, 2017. Cited 196+

Contact

Let's connect.

Open to opportunities in biopharmaceutical process development, gene therapy, and translational research. I'd be glad to hear from you.